The current valuation score of CureVac NV is 8.25, ranking 58 out of 401 in the Biotechnology & Medical Research industry. Its current P/E ratio is 9.59, which is 17.81% below the recent high of 11.30 and 237.04% above the recent low of -13.15.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.